Stockscreener 앱 받기
64.40
3.98%
-2.67
전일 마감가:
$67.07
열려 있는:
$67.46
하루 거래량:
37,706
Relative Volume:
0.99
시가총액:
$2.08B
수익:
-
순이익/손실:
$-32.61M
주가수익비율:
-54.85
EPS:
-1.1742
순현금흐름:
-
1주 성능:
+5.40%
1개월 성능:
+12.43%
6개월 성능:
-22.23%
1년 성능:
+51.94%
1일 변동 폭
$64.38
$67.51
1주일 범위
$60.01
$67.91
52주 변동 폭
$41.88
$86.53
Belite Bio Inc Adr Stock (BLTE) Company Profile
BLTE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
64.40 | 1.97B | 0 | -32.61M | 0 | -1.1742 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-14 | 개시 | Maxim Group | Buy |
| 2023-07-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-26 | 개시 | SVB Securities | Outperform |
| 2022-08-01 | 개시 | H.C. Wainwright | Buy |
| 2022-07-01 | 개시 | The Benchmark Company | Buy |
Belite Bio Inc Adr 주식(BLTE)의 최신 뉴스
Belite Bio (NASDAQ:BLTE) Earns “Overweight” Rating from Cantor Fitzgerald - Defense World
HC Wainwright Reaffirms Buy Rating for Belite Bio (NASDAQ:BLTE) - Defense World
Benchmark maintains Buy on Belite Bio stock, $80 price target unchanged - Investing.com Nigeria
Belite Bio’s Earnings Call Highlights Clinical Progress and Financial Strength - TipRanks
Belite Bio at Deutsche Bank Conference: Promising Drug Trials By Investing.com - Investing.com India
Transcript : Belite Bio, Inc Presents at Deutsche Bank ADR Virtual Investor Conference, May-15-2025 12 - marketscreener.com
Belite Bio at Deutsche Bank Conference: Promising Drug Trials - Investing.com
Belite Bio stock retains Overweight rating at Cantor Fitzgerald - Investing.com Australia
Promising Clinical Trials and Strategic Developments Justify Buy Rating for Belite Bio - TipRanks
Belite Bio Advances Clinical Trials Amid Financial Challenges - TipRanks
Earnings call transcript: Belite Bio’s Q1 2025 sees narrower EPS loss - Investing.com Nigeria
Earnings Flash (BLTE) Belite Bio Q1 Loss $0.45 Vs. FactSet Est. $0.35 Loss - marketscreener.com
Belite Bio Q1 2025 Earnings Call Transcript - MarketBeat
Belite Bio Advances Tinlarebant Trials with Positive Interim Results - TipRanks
Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - ADVFN
Belite Bio reports Q1 EPS (45c), consensus (37c) - TipRanks
Belite Bio's Stargardt Disease Drug Passes Critical Phase 3 Trial Review, DSMB Suggests Regulatory Filing - Stock Titan
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - GlobeNewswire Inc.
Belite Bio, Inc to Present at the dbVICDeutsche Bank ADR Virtual Investor Conference May 15th - GlobeNewswire
Belite Bio to Participate in Four Upcoming Investor Conferences - Stock Titan
Belite Bio (BLTE) to Release Quarterly Earnings on Monday - Defense World
International companies to host live webcasts at Deutsche - GlobeNewswire
UPDATEInternational companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Manila Times
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Manila Times
Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results - Stock Titan
The 9 Best Stocks to Buy Now in May (2025)! - The Globe and Mail
Breakthrough: Belite Bio Presents Critical Data from Two Stargardt Disease Clinical Trials at ARVO 2025 - Stock Titan
Belite Bio, Inc (NASDAQ:BLTE) Shares Purchased by JPMorgan Chase & Co. - Defense World
Brokers Offer Predictions for Belite Bio FY2028 Earnings - Defense World
Belite Bio shareholders approve all resolutions at AGM By Investing.com - Investing.com South Africa
Belite Bio Announces Key Resolutions from 2025 General Meeting - TipRanks
Belite Bio shareholders approve all resolutions at AGM - Investing.com
Stargardt Disease Market Predicted to See Upsurge Through 2034, - openPR.com
Belite Bio, Inc. Appoints New Auditor - TipRanks
Benchmark Reiterates Buy Rating for Belite Bio (NASDAQ:BLTE) - Defense World
Belite Bio stock target raised to $80 at Benchmark By Investing.com - Investing.com South Africa
Belite Bio price target raised to $80 from $79 at Benchmark - TipRanks
Belite Bio stock target raised to $80 at Benchmark - Investing.com
Belite Bio, Inc. ADR: Promising Clinical Progress and Strong Financial Position Drive Buy Rating - TipRanks
Cantor Fitzgerald Expects Reduced Earnings for Belite Bio - The AM Reporter
Cantor Fitzgerald Forecasts Weaker Earnings for Belite Bio - Defense World
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Up 17.1% in February - Defense World
HC Wainwright Has Pessimistic View of Belite Bio Q1 Earnings - Defense World
Belite Bio (NASDAQ:BLTE) Receives Buy Rating from HC Wainwright - Defense World
Belite Bio’s (BLTE) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
Belite Bio’s Earnings Call: Cautious Optimism Amid Progress - TipRanks
Belite Bio Announces 2025 Annual Shareholder Meeting - TipRanks
Belite Bio stock holds $100 target post-results By Investing.com - Investing.com India
Belite Bio stock holds $100 target post-results - Investing.com
Positive Buy Rating for Belite Bio, Inc. Driven by Promising Phase 3 DRAGON Trial Results and Regulatory Prospects - TipRanks
Belite Bio Inc Adr (BLTE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
7.58%
자본화:
|
볼륨(24시간):